The purpose of this study is to understand the characteristics of adults diagnosed with with clinically palpable stage III resectable melanoma, the associated treatment patterns for their disease, and outcomes associated with the real-world use of neoadjuvant nivolumab+relatlimab or nivolumab+ipilimumab

Inclusion Criteria:

• Participants at least 18 years old at diagnosis of clinically palpable stage III resectable melanoma
• Participants treated with nivolumab+relatimab (nivo+rela) or nivolumab+ipilimumab (nivo+ipi) in the neoadjuvant setting
• Participants with at least 6 months of follow-up from initiation of neoadjuvant therapy, unless deceased prior to 6 months of follow-up

Exclusion Criteria:

• Participants received nivo+rela or nivo+ipi for clinically palpable stage III resectable melanoma as part of a therapeutic clinical trial
• Participants had history of diagnosis of any malignancy (except for non-melanoma skin cancer) in the last 2 years.
• Participants received adjuvant nivo+rela or adjuvant nivo+ipi after neoadjuvant nivo+ipi
• Participants received adjuvant nivo+ipi after neoadjuvant nivo+rela
• Participants received any systemic therapy prior to the initiation of neoadjuvant nivo+rela or nivo+ipi

The study population will comprise of adult diagnosed with clinically palpable stage III resectable melanoma in the U.S. managed by physicians in Cardinal Health's OPEN treated with neoadjuvant nivolumab+relatimab or nivolumab+ipilimumab from 18 March 2022.